SANTA ANA, CA--(Marketwired - Jun 17, 2013) - BioLargo, Inc. (
Dennis Calvert, President & CEO of BioLargo, stated, "We believe that our BioLargo® AOS Filter represents a revolutionary technical advancement in how water should be treated. With the completion of the proof of claim work at the University of Alberta, we plan to focus on engineering and specific contaminant testing as we continue to position the product for commercial opportunities. We also plan to focus on adding key executives and strategic partners to aid us in building the business. Our AOS Filter can be of great benefit to industry as they deal with regulatory pressures to find a sustainable way to rid water of dangerous contaminants. Global Water Intelligence, a leading industry journal provides the most widely used estimate of the global water market at approximately $360 billion annual revenues per year. Estimates put the 'component technologies' portion at approximately 10% of the global market revenue figures. We believe our AOS Filter will compete in this component technologies area.
"Our AOS Filter should have an important role to play in most of this industry's segments, including oil and gas, refining and petrochemicals, power generation, food and beverage, pharmaceuticals, microelectronics, pulp and paper, and mining. It could serve as a platform to build an integrated water company featuring technology, licensing, engineering and services. While there is much work to do, we are excited about the significant opportunities ahead."
Kenneth Reay Code, BioLargo Chief Science Officer and inventor of the BioLargo® AOS Filter, added, "Many industry segments, like energy and industrial process water systems, use extremely high volumes of water in their daily business activity. Often, tiny organic molecules, including soluble contaminants, are problematic for these types of water uses. We also know that many industry segments require ultra pure water. These industries need a treatment system that can manage high volumes of water with constant process performance and a high level of efficiency that is sustainable in term of safety and cost. With our AOS Filter, have been able to prove a level of performance in which our system dismantles organic contaminants to their basic molecular forms in minutes, rendering them safe. Other systems can take years, as in the case of settling ponds, or hours for other advanced oxidation technologies like UV and Ozone."
The company cautions that this market is highly competitive and dominated by global companies that have far greater capital, sales and expertise with established market share. To compete in this market, the company will require substantial resources that are currently not available. Further, its products will require regulatory approvals to market the AOS Filter with these claims. To seek regulatory approval, the new subsidiary will require investment capital to complete product development, build prototype products, complete testing, and make such applications.
About BioLargo, Inc.
We make life better by delivering technology-based products that help solve some of the world's most important problems that threaten our water, food, agriculture, healthcare and energy. Our website is www.BioLargo.com. Our Odor-No-More Inc. subsidiary features award-winning products serving the companion animal and equine markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. Our subsidiary, Clyra Medical Technologies, Inc., focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2013.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.